Burdett M*, Mestayer R, Olds T
Alzheimer’s disease is a terminal, degenerative neuromuscular disease that affects cognition, motor function, and, occasionally, personality. While a cure has yet to be found, there have been drugs created to slow the progression of the disease. In this report, we describe the effect that IV NAD BR+ (nicotinamide adenine dinucleotide brain restoration plus) infusions had on an Alzheimer’s patient and his symptoms. The patient is a 73-year-old male who was diagnosed with Alzheimer’s Disease in 2013. The patient was prescribed Namenda XR, and, in April of 2015, began NAD infusion treatments, along with continued Namenda. Only 3 months later, there was a notable subjective improvement in the patient’s memory and attitude. The patients decline following missed treatments due to COVID-19, and his subsequent treatments and their outcomes have been documented as well.
Published Date: 2021-02-15; Received Date: 2021-02-17